Imricor Medical Systems, whose shares have been on a tear since its last equity raising in July 2024, needs more cash to it get through to US Food and Drug Administration approvals for its flagship products.
Imricor was first out the gates with a capital raising on Monday. Dominic Lorrimer
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
